Endocrine
VIPoma
Also known as Verner-Morrison syndrome, pancreatic cholera, WDHA syndrome, vasoactive intestinal peptide tumor
VIPoma is a rare pancreatic or extra-pancreatic neuroendocrine tumour that secretes excess vasoactive intestinal peptide (VIP), causing a distinctive syndrome of profuse watery diarrhoea, hypokalaemia, and achlorhydria collectively termed W
0
studies recruiting now
as of 7 Sept 2026
23
studies registered in total
as of 7 Sept 2026
0
countries with a recruiting site
as of 7 Sept 2026
None
recruiting study posted to date
among recruiting studies
Recruiting trials
No recruiting trial found right now.
23 studies are registered for VIPoma, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.
Keep watching
Get an email when a new VIPoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: NANETS Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About VIPoma
VIPoma is a rare pancreatic or extra-pancreatic neuroendocrine tumour that secretes excess vasoactive intestinal peptide (VIP), causing a distinctive syndrome of profuse watery diarrhoea, hypokalaemia, and achlorhydria collectively termed WDHA syndrome or Verner-Morrison syndrome. The massive secretory diarrhoea, which persists even with fasting, leads to severe electrolyte disturbances, dehydration, and metabolic acidosis that can be life-threatening if untreated. Over 50% of VIPomas are malignant at the time of diagnosis, with liver metastases commonly present, making systemic therapy trials particularly relevant for this tumour type.
Common clinical features
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for VIPoma. Not eligibility rules; those are set by each study.
- Elevated fasting plasma VIP level (typically greater than 200 pg/mL) combined with characteristic symptoms and imaging evidence of a pancreatic or retroperitoneal mass is required for trial eligibility confirmation.
- Correction of electrolyte abnormalities (particularly hypokalaemia) to safe levels before screening is a standard requirement; recent electrolyte results and repletion history should be documented.
- Functional imaging with 68Ga-DOTATATE PET or octreotide scan assessing somatostatin receptor expression is required for trials of somatostatin analogues or PRRT; receptor positivity is often an eligibility criterion.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).